As a Tekmira investor, you know you’re living and dying (no pun intended) by the amount of Ebola cases reported and the WHO’s sentiment on the worldwide breakout. Should the WHO come out and declare the emergency over, Tekmira shares would likely start walking back down to their pre-hype $10 levels.
The WHO issued a bulletin today, updating the world on their stance on the Ebola crisis.
You can read the bulletin here, but I’ve copied the content of the release into the article below:
Clinicians working in Liberia have informed WHO that 2 doctors and 1 nurse have now received the experimental Ebola therapy, ZMapp.
The nurse and one of the doctors show a marked improvement. The condition of the second doctor is serious but has improved somewhat.
According to the manufacturer, the very limited supplies of this experimental medicine are now exhausted.
ZMapp is one of several experimental treatments and vaccines for Ebola that are currently undergoing investigation. At present, supplies of all are extremely limited.
On 4–5 September, WHO will host a consultation on potential Ebola therapies and vaccines in Geneva. The consultation has been convened to gather expertise about the most promising experimental therapies and vaccines and their role in containing the Ebola outbreak in west Africa.
The expertise among the more than 100 participants is wide, ranging from pharmaceutical research and the clinical demands of Ebola care, to expertise on ethical, legal, and regulatory issues. More than 20 experts from west Africa are expected to attend.
Issues of safety and efficacy will be discussed together with innovative models for expediting clinical trials. Possible ways to ramp up production of the most promising products will also be explored.
Presentations about the real conditions and challenges in affected African countries are intended to anchor all discussions and shape the consensus advice that is expected to emerge.
As you can see, while the successful ZMapp has been mentioned by name, the WHO failed to say anything about Tekmira’s drug in this release. This comes a day after Tekmira played “let’s make a deal” with African governments in order to get its drug onto the continent.
This also comes one day after longs bought in a euphoric rage because one of Tekmira’s other drugs worked on a disease that was not Ebola (it’s labeled as Ebola’s cousin) – in monkeys.
And what’s with this conference being scheduled to “explore safety and efficacy” on 9/4 – the WHO doesn’t seem to be in a rush, do they? Could it be possibly this pandemic is going to pass before the end of the year? QTR thinks so.
Yes, apparently this has become an investment thesis for buying a $400-$500M market cap company with nothing but net losses in its past. Beats me.
We saw today what we’ve been seeing from TKMR – weak trading. A gap open and a flush out when liquidity hits. God help this stock on a day when the market decides to correct 1% or so.
There’s also been a ton of people that have given me the business about how many articles I’ve written over the span of about 1 year and 8 months. That total on Seeking Alpha is now around X and yes, I personally wrote every single one of them. I love to write and get my thoughts down and I love the platform that Seeking Alpha provided for me. I’d give these insults a second thought if the amount I was writing was diluting the content of my articles, but according to TipRanks – after 847 articles – the results aren’t too shabby.
And that’s with a massive QCOR loss priced in – which, again, I contest will come back around my way.
I remain short TKMR via puts – added some today.
Catch you on the flip side,